HIGHLIGHTS
- who: CDH and collaborators from the Fudan University, China have published the research: CDH6 as a prognostic indicator and marker for chemotherapy in gliomas, in the Journal: (JOURNAL)
SUMMARY
Patients with GBM have a 5-years survival rate of less than 10% (Stupp et_al, 2009; Weller et_al, 2017). The development of immunotherapy has improved the treatment outcome in several cancers in humans (Kim et_al, 2020; Wang et_al, 2021). Immune checkpoint inhibitors, such as antiprogrammed death-1 (PD-1), and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies enhance the activity of T_cells and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.